Lyell Immunopharma Stock (NASDAQ:LYEL)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$12.42

52W Range

$7.65 - $34.40

50D Avg

$9.63

200D Avg

$13.19

Market Cap

$212.23M

Avg Vol (3M)

$144.41K

Beta

-0.24

Div Yield

-

LYEL Company Profile


Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

300

IPO Date

Jun 17, 2021

Website

LYEL Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 24
Reportable segment$61.00K

Fiscal year ends in Dec 24 | Currency in USD

LYEL Financial Summary


Dec 24Dec 23Dec 22
Revenue-$130.00K$84.68M
Operating Income$-3.31M$-247.01M$-183.12M
Net Income$-342.99M$-234.63M$-4.75M
EBITDA$-3.31M$-226.76M$-166.65M
Basic EPS$-1.31$-0.93$-0.02
Diluted EPS$-1.31$-0.93$-0.02

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison


TickerCompany
IPSCCentury Therapeutics, Inc.
SANASana Biotechnology, Inc.
KROSKeros Therapeutics, Inc.
ERASErasca, Inc.
GLUEMonte Rosa Therapeutics, Inc.
TILInstil Bio, Inc.